产品名称

523

1893

体外研究（In Vitro Assay）：

细胞类型（Cell type）：BGC-823 and GSE-1 cell

实验方法（Cell viability assay）：The sulforhodamine B (SRB) assay was performed as described to measure BGC-823 and GSE-1 cell viability after DATS treatment. Briefly, 3.0×103 cells/well were grown in 96-well plates for 12 h and exposed todifferent concentrations of DATS (0–400 μmol/L) for 24 or 48 h.

体内研究（In Vivo Assay）：

动物模型（Animal Model）：Tumor xenograft mice model

实验方法（Assay）：To establish gastric carcinoma xenograft tumors in mice, BGC-823 cells (5.0×106) were suspended in 100 μL PBS and subcutaneously injected into the mice. The mice were sacrificed a month later. The tumor was separated by 2 mm fragments and implanted into other mice. When tumor volumes reached approximately 100 mm3,mice were randomized and assigned to the following treatments: control (normal saline, containing 20% β-cycloamylose, every day); cisplatin (5 mg/kg, positive control, every 5 d); treated groups (DATS was formed with β-cycloamylose and dissolved in normal saline, dosage at 20, 30 or 40 mg·kg−1·d−1); and the co-treated group (cisplatin, 5 mg/kg every 5 d and DATS at 30 mg/kg all other days). All mice were sacrificed on the 32nd day,and the tumors were excised for weight measurement and histopathological analysis.

体内研究（In Vivo Assay）：

动物模型（Animal Model）：Tumor xenograft mice model

配制方法（Formulation）：DATS was maintained in sealed amber glass ampules and kept at−20°C until use. On the day of experimentation, a fresh glass ampule of DATS was opened. DATS (5μl) was diluted in 500 μl of 100% DJPO. For in vivo experiments, the DATS in 100% DJPO solution was further diluted in sterile saline to obtain the correct dosage to be delivered in a volume of 50 μl. The resulting concentration of DJPO in this dosage was 1%. Vehicle consisted of a solution of 1% DJPO in sterile saline.

实验方法（Assay）：DATS was administered at 200 μg/kg before reperfusion by either an intravenous injection 5 min before reperfusion or an intraperitoneal injection 22.5 min before reperfusion.After 24 h of reperfusion, the LV area at risk (AAR) and infarct size were determined by Evan’s blue and 2,3,5-tetrazolium chloride staining, as previously described.

Jinpan

2050-87-5

100mg

咨询客服

产品名称

523

1893

体外研究（In Vitro Assay）：

细胞类型（Cell type）：BGC-823 and GSE-1 cell

实验方法（Cell viability assay）：The sulforhodamine B (SRB) assay was performed as described to measure BGC-823 and GSE-1 cell viability after DATS treatment. Briefly, 3.0×103 cells/well were grown in 96-well plates for 12 h and exposed todifferent concentrations of DATS (0–400 μmol/L) for 24 or 48 h.

体内研究（In Vivo Assay）：

动物模型（Animal Model）：Tumor xenograft mice model

实验方法（Assay）：To establish gastric carcinoma xenograft tumors in mice, BGC-823 cells (5.0×106) were suspended in 100 μL PBS and subcutaneously injected into the mice. The mice were sacrificed a month later. The tumor was separated by 2 mm fragments and implanted into other mice. When tumor volumes reached approximately 100 mm3,mice were randomized and assigned to the following treatments: control (normal saline, containing 20% β-cycloamylose, every day); cisplatin (5 mg/kg, positive control, every 5 d); treated groups (DATS was formed with β-cycloamylose and dissolved in normal saline, dosage at 20, 30 or 40 mg·kg−1·d−1); and the co-treated group (cisplatin, 5 mg/kg every 5 d and DATS at 30 mg/kg all other days). All mice were sacrificed on the 32nd day,and the tumors were excised for weight measurement and histopathological analysis.

体内研究（In Vivo Assay）：

动物模型（Animal Model）：Tumor xenograft mice model

配制方法（Formulation）：DATS was maintained in sealed amber glass ampules and kept at−20°C until use. On the day of experimentation, a fresh glass ampule of DATS was opened. DATS (5μl) was diluted in 500 μl of 100% DJPO. For in vivo experiments, the DATS in 100% DJPO solution was further diluted in sterile saline to obtain the correct dosage to be delivered in a volume of 50 μl. The resulting concentration of DJPO in this dosage was 1%. Vehicle consisted of a solution of 1% DJPO in sterile saline.

实验方法（Assay）：DATS was administered at 200 μg/kg before reperfusion by either an intravenous injection 5 min before reperfusion or an intraperitoneal injection 22.5 min before reperfusion.After 24 h of reperfusion, the LV area at risk (AAR) and infarct size were determined by Evan’s blue and 2,3,5-tetrazolium chloride staining, as previously described.

Jinpan

2050-87-5

25mg

咨询客服

产品名称

523

1893

体外研究（In Vitro Assay）：

细胞类型（Cell type）：BGC-823 and GSE-1 cell

实验方法（Cell viability assay）：The sulforhodamine B (SRB) assay was performed as described to measure BGC-823 and GSE-1 cell viability after DATS treatment. Briefly, 3.0×103 cells/well were grown in 96-well plates for 12 h and exposed todifferent concentrations of DATS (0–400 μmol/L) for 24 or 48 h.

体内研究（In Vivo Assay）：

动物模型（Animal Model）：Tumor xenograft mice model

实验方法（Assay）：To establish gastric carcinoma xenograft tumors in mice, BGC-823 cells (5.0×106) were suspended in 100 μL PBS and subcutaneously injected into the mice. The mice were sacrificed a month later. The tumor was separated by 2 mm fragments and implanted into other mice. When tumor volumes reached approximately 100 mm3,mice were randomized and assigned to the following treatments: control (normal saline, containing 20% β-cycloamylose, every day); cisplatin (5 mg/kg, positive control, every 5 d); treated groups (DATS was formed with β-cycloamylose and dissolved in normal saline, dosage at 20, 30 or 40 mg·kg−1·d−1); and the co-treated group (cisplatin, 5 mg/kg every 5 d and DATS at 30 mg/kg all other days). All mice were sacrificed on the 32nd day,and the tumors were excised for weight measurement and histopathological analysis.

体内研究（In Vivo Assay）：

动物模型（Animal Model）：Tumor xenograft mice model

配制方法（Formulation）：DATS was maintained in sealed amber glass ampules and kept at−20°C until use. On the day of experimentation, a fresh glass ampule of DATS was opened. DATS (5μl) was diluted in 500 μl of 100% DJPO. For in vivo experiments, the DATS in 100% DJPO solution was further diluted in sterile saline to obtain the correct dosage to be delivered in a volume of 50 μl. The resulting concentration of DJPO in this dosage was 1%. Vehicle consisted of a solution of 1% DJPO in sterile saline.

实验方法（Assay）：DATS was administered at 200 μg/kg before reperfusion by either an intravenous injection 5 min before reperfusion or an intraperitoneal injection 22.5 min before reperfusion.After 24 h of reperfusion, the LV area at risk (AAR) and infarct size were determined by Evan’s blue and 2,3,5-tetrazolium chloride staining, as previously described.